Danish pharmaceutical giant Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new CEO, replacing Lars Fruergaard Jørgensen. The company revised financial estimates, forecasting sales growth of between 8% and 14%, below previous expectations. The statement sent shares down 23%. The revision is due to weak expectations for sales of Wegovy and Ozempic drugs in the U.S. amid increased competition and use of compounded drugs. Doustdar, with over 30 years of experience in the company, promises to focus efforts on innovation and performance.
Sources
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Bursă. Business internaţional. Scădere de 20% ieri pe acţiunile Novo Nordisk, cândva cea mai valoroasă companie europeană Grupul farmaceutic danez Novo Nordisk a anunţat marţi o revizuire în scădere a estimărilor de vânzări şi profit pentru 2025, din cauza încetinirii creşterii în Statele Unite...
Acțiunile Novo Nordisk s-au prăbușit
Latest News
13:36
Nicusor Dan calls for balance and says Romania is not “on the brink of apocalypse”
13:04
The Finance Ministry increases funding for energy reimbursements and the payment of benefits for people with disabilities
12:43
The Bucharest Court of Appeal annulled the awarding of lots 1 and 2 of the Suceava–Siret Expressway and ordered CNAIR to reevaluate the bids
12:34
Suceava Gendarmerie warns the public after a bear was seen in Rădășeni and Fălticeni and captured on camera in the Dumbrava Minunată area
12:19
Romania will shift from summer temperatures to cold weather and possible snowfall in the mountains
See more news